Apocrine carcinoma of the male breast is an exceptional malignant tumor. It does not have a particular clinical or radiological appearance, but it's microscopically characterized by the presence of granular cells and foamy cells representing over 90% of tumor cells. These cells express most of the time the GCDFP-15 and the androgen receptors. This tumor is a distinct molecular entity. In this observation, we report the case of a 70 year old man presenting apocrine carcinoma of the left breast diagnosed at the stage of lung metastasis.
Introduction
Apocrine carcinoma of the breast is a malignant tumor, microscopically characterized by the presence of granular cells and foamy cells representing over 90% of tumor cells. It does not have a particular clinical or radiological appearance, but it's a distinct molecular entity. We report an exceptional observation of apocrine carcinoma of breast in a man.
Patient and observation
He's a 70 years old man who had for 9 years ago a painless nodule at the left breast. It was movable relative to superficial and deep plans. Then, this nodule presented a rapid augmentation of its volume with adhesion to both superficial and deep plans, and inflammatory opposite signs. Mammography showed an ACR5 lesion measuring 4 cm long axis. We realized a fine-needle aspiration cytology, a spread on slides and stained with May-Grünwald Giemsa 
Discussion
Apocrine carcinoma of the breast is a rare malignant tumor whose incidence varies between 0.3% and 4% of all female's breast cancer [1] . This tumor is exceptional in men. Indeed, only a dozen cases have been described in the literature [2] . Like our patient, the average age of onset is between the sixth and seventh decade [1] .
Its clinical mammographic and sonographic characteristics mimic those of non-apocrine breast invasive carcinoma. The cytology after fine needle aspiration may have a role in orienting. As in our patient, it shows apocrine cells with cell and nuclear atypias, a large irregular nucleus and a prominent nucleolus with abundant cytoplasm [3] . Macroscopically, apocrine carcinoma is in the form of a nodule or endo-cystic growths, often multicentric [1] .
Histologically, the tumor is defined as a carcinoma showing in more Although apocrine carcinoma is a distinct histological entity, however, there is no sensitive and specific immunohistochemical marker for confirming apocrine differentiation.
Immunohistochemical study shows an expression of GCDFP-15 in 76% to 100% of cases. The GCDFP-15 is a glycoprotein originally isolated from breast cyst fluid. It's localized in cytoplasmic vesicles, and in osmiophilic granules. With the development of this marker, a more objective diagnostic criterion has been introduced [4] .
Androgen receptors are expressed in 54% of cases [5] . Moreover, tumor cells can express B72.3, estrogenic-beta receptors, HER2, p53 and Ki-67 [1] . Usually, these tumors do not express the estrogen receptor-alpha, progesterone receptors and bcl-2. [1] Concerning the molecular study, we note the presence of abnormalities in the long arm of chromosome 7 (genes encoding the GCDFP-15 and prolactin-inducible protein), also the loss of heterozygosity for the TP53 gene, the VHL gene (3p25), the NB gene (1p35-36), and PKD1/TSC2 gene (16p13) [6] . The new molecular classification of breast cancers based on studies of CGHarray, classifies apocrine carcinoma individually [7] .
Page number not for citation purposes 3 Treatment protocols are similar to those of non-apocrine carcinoma.
However, studies involving the use of anti-androgens are in progress [6] . The survival rate at 5 years was significantly better for the apocrine carcinoma (72%) with a longer time to recurrence compared to non-apocrine carcinoma. Prognostic factors are essentially the mitotic account and TNM stage. [1] 
Conclusion
Apocrine carcinoma of the breast is a distinct histological and molecular entity. It is rare in women and exceptional in man.
Studies are being conducted to use anti-androgens such as targeted therapy.
Competing interests
Authors declare no competing interests.
Authors' contributions
Authors contributed to the diagnosis of this tumor, revising critically the article for important intellectual content; and final approval of the version to be published. 
